Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial

Lancet

Volumn 361, Issue 9364, 2003, Pages 1149-1158

  Sever, Peter S ^a   Dahlöf, Björn ^b   Poulter, Neil R ^a   Wedel, Hans ^c   Beevers, Gareth ^d   Caulfield, Mark ^e   Collins, Rory ^f   Kjeldsen, Sverre E ^g   Kristinsson, Arni ^h   McInnes, Gordon T ⁱ   Mehlsen, Jesper ^j   Nieminen, Markku ^k   O'Brien, Eoin ^l   Östergren, Jan ^m  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d CITY HOSPITAL   (United Kingdom)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f RADCLIFFE INFIRMARY   (United Kingdom)

^g ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^h LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

^j FREDERIKSBERG HOSPITAL   (Denmark)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l BEAUMONT HOSPITAL   (Ireland)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DEATH; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 0037420492     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12948-0     Document Type: Article

References (33)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335:1996;1001-1009.
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339:1998;1349-1357.
4. Athyros V.G., Papageorgiou A.A., Mercouris B.R. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Curr Med Res Opin. 18:2002;220-228.
5. Serruys P.W., de Feyter P., Macaya C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomised controlled trial. JAMA. 287:2002;3215-3222.
6. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
7. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 279:1998;1615-1622.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 360:2002;7-22.
9. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360:2002;1623-1630.
10. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care. JAMA. 288:2002;2998-3007.
11. Woolf N. Pathology of atherosclerosis. Betteridge D.J., Illingworth R., Shepherd J. Lipoproteins in health and disease. 1999;Arnold, London.
12. Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA. 256:1986;2823-2828.
13. Bloomfield Rubins H., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
14. Buchwald H., Varco R.L., Matts J.P., et al. Report of the program on the surgical control of the hyperlipidemias (POSCH): effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. N Engl J Med. 323:1990;946-955.
15. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet. 352:1998;1801-1807.
16. Crouse J.R. III, Byington R.P., Furberg C.D. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 138:1998;11-24.
17. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA. 285:2001;1711-1718.
18. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. Lancet. 2:1986;933-936.
19. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 18:2000;207-213.
20. Kannel W.B. Importance of hypertension as a major risk factor in cardiovascular disease. Bosch J., Grozsmann R.J. Hypertension: physiopathology and treatment. 1999;888-910 McGraw Hill, New York.
21. Stamler R. The primary prevention of hypertension and the population blood pressure problem. Marmot M., Elliott P. Coronary heart disease epidemiology. 1992;Oxford Medical Publications, Oxford.
22. Sever P.S., Dahlöf B., Poulter N.R., et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens. 6:2001;1139-1147.
23. Hansson L., Hedner T., Dahlof B. Prospective Randomised Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Pressure. 1:1992;113-119.
24. Anglo-Scandinavian Cardiac Outcomes trial. ASCOT http://www.ascotstudy.co.uk (accessed March 14, 2003).
25. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 103:2001;357-362.
26. Bucher H.C., Griffith L.E., Guyatt G.H. Systematic review on the riskand benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 19:1999;187-195.
27. Ramsay L.E., Williams B., Johnston G.D., et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society, 1999. J Hum Hypertens. 13:1999;569-592.
28. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens. 16:1998;127-137.
29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2487-97.
30. Ramsay L.E., Haq I.Q., Jackson P.R., Yeo W.W., Pickin D.M., Payne J.N. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 348:1996;387-388.
31. Wood D., Durrington P., Poulter N., McInnes G., Rees A., Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 80:1998;S1-S29.
32. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the MHG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 34:1999;1281-1286.
33. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Eur Heart J. 22:2001;554-572.